3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Multiple Myeloma
4
Neoplasm, Residual
3
Neoplasm Metastasis
3
Carcinoma, Non-Small-Cell Lung
3
Colorectal Neoplasms
2
Pancreatic Neoplasms
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Myeloid, Acute
1
Fallopian Tube Neoplasms
1
Burkitt Lymphoma
1
Interventions
Filgrastim
9
Ifosfamide
8
Etoposide
8
Doxorubicin
8
Cyclophosphamide
8
Vincristine
7
X-Rays
6
Radiotherapy
6
Phantoms, Imaging
6
Magnetic Resonance Spectroscopy
6
Specimen Handling
5
Nuclear Medicine Department, Hospital
5
Topotecan
4
Peripheral Blood Stem Cell Transplantation
4
Melphalan
4
Irinotecan
4
Biopsy
4
Thiotepa
3
Imatinib Mesylate
3
Carboplatin
3
Bevacizumab
3
ulixertinib
2
tipifarnib
2
temsirolimus
2
tazemetostat
2
selpercatinib
2
palbociclib
2
olaparib
2
larotrectinib
2
ivosidenib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neuroectodermal Tumors, Primitive, Peripheral
×
Maintenance
×
Clear all
NCT03011528
2025-11-21
CombinaiR3
Institut Curie
Phase 2
Completed
45 enrolled